phosphorus has been researched along with tenapanor in 9 studies
| Studies (phosphorus) | Trials (phosphorus) | Recent Studies (post-2010) (phosphorus) | Studies (tenapanor) | Trials (tenapanor) | Recent Studies (post-2010) (tenapanor) |
|---|---|---|---|---|---|
| 48,074 | 1,126 | 17,139 | 41 | 16 | 40 |
| Protein | Taxonomy | phosphorus (IC50) | tenapanor (IC50) |
|---|---|---|---|
| Sodium/hydrogen exchanger 3 | Rattus norvegicus (Norway rat) | 0.0115 | |
| Sodium/hydrogen exchanger 3 | Homo sapiens (human) | 0.0035 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (44.44) | 24.3611 |
| 2020's | 5 (55.56) | 2.80 |
| Authors | Studies |
|---|---|
| Bell, N; Black, D; Carreras, CW; Charmot, D; Deshpande, D; Dy, E; He, L; Jacobs, JW; Kohler, J; Koo-McCoy, S; Kozuka, K; Labonté, ED; Langsetmo, I; Leadbetter, MR; Lewis, JG; Navre, M; Spencer, AG; Zhong, Z | 1 |
| Johansson, S; Knutsson, M; Leonsson-Zachrisson, M; Rosenbaum, DP | 1 |
| Charmot, D; Deshpande, D; Johansson, S; Knutsson, M; Kohler, J; Kozuka, K; Labonté, ED; Leonsson-Zachrisson, M; Rosenbaum, DP; Spencer, AG | 1 |
| Johansson, SA; Knutsson, M; Leonsson-Zachrisson, M; Rosenbaum, DP | 1 |
| Chertow, GM; Fung, C; Jiang, Z; King, AJ; Kohler, J; Kumaraswamy, P; Quach, A; Rosenbaum, DP | 1 |
| Chertow, GM; Pergola, PE; Rosenbaum, DP; Yang, Y | 1 |
| Akizawa, T; Fukagawa, M; Ikejiri, K; Kanda, H; Shigematsu, T; Une, Y | 1 |
| Ai, X; Dong, H; Feng, J; Huang, B; Huang, X; Li, J; Li, L; Li, X; Luo, H; Wang, J; Xiao, H; Xue, G; You, S; Zhang, Y | 1 |
| Akizawa, T; Fukagawa, M; Koiwa, F; Nakanishi, K; Ohara, M; Sato, Y | 1 |
1 review(s) available for phosphorus and tenapanor
| Article | Year |
|---|---|
Efficacy and safety of tenapanor in hemodialysis patients with hyperphosphatemia: A systematic review and meta-analysis of randomized placebo-controlled trials.
Topics: Diarrhea; Double-Blind Method; Humans; Hyperphosphatemia; Phosphorus; Randomized Controlled Trials as Topic; Renal Dialysis | 2023 |
6 trial(s) available for phosphorus and tenapanor
| Article | Year |
|---|---|
A phase 1 study of the safety, tolerability, pharmacodynamics, and pharmacokinetics of tenapanor in healthy Japanese volunteers.
Topics: Adult; Asian People; Double-Blind Method; Drug Administration Schedule; Feces; Female; Gastrointestinal Agents; Healthy Volunteers; Humans; Intestinal Absorption; Intestinal Mucosa; Intestines; Isoquinolines; Japan; Male; Middle Aged; Phosphorus; Sodium; Sodium-Hydrogen Exchanger 3; Sulfonamides; Young Adult | 2017 |
Preclinical and Healthy Volunteer Studies of Potential Drug-Drug Interactions Between Tenapanor and Phosphate Binders.
Topics: Adult; Animals; Cross-Over Studies; Drug Administration Schedule; Drug Evaluation, Preclinical; Drug Interactions; Female; Healthy Volunteers; Humans; Isoquinolines; Male; Middle Aged; Phosphorus; Random Allocation; Rats; Sevelamer; Sodium; Sulfonamides | 2017 |
Effect of Food Intake on the Pharmacodynamics of Tenapanor: A Phase 1 Study.
Topics: Adult; Cross-Over Studies; Drug Administration Schedule; Feces; Female; Healthy Volunteers; Humans; Isoquinolines; Male; Middle Aged; Phosphorus; Random Allocation; Sodium, Dietary; Sulfonamides; Young Adult | 2017 |
A Randomized Trial of Tenapanor and Phosphate Binders as a Dual-Mechanism Treatment for Hyperphosphatemia in Patients on Maintenance Dialysis (AMPLIFY).
Topics: Adult; Aged; Chelating Agents; Diarrhea; Double-Blind Method; Drug Therapy, Combination; Female; Fibroblast Growth Factor-23; Humans; Hyperphosphatemia; Isoquinolines; Male; Middle Aged; Phosphorus; Renal Dialysis; Renal Insufficiency, Chronic; Sevelamer; Sodium-Hydrogen Exchanger 3; Sulfonamides | 2021 |
Therapeutic Effects of Add-On Tenapanor for Hemodialysis Patients with Refractory Hyperphosphatemia.
Topics: Aged; Chelating Agents; Diarrhea; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Hyperphosphatemia; Isoquinolines; Male; Medication Adherence; Middle Aged; Phosphorus; Renal Dialysis; Renal Insufficiency, Chronic; Sodium-Hydrogen Exchangers; Sulfonamides | 2021 |
Long-term safety and decrease of pill burden by tenapanor therapy: a phase 3 open-label study in hemodialysis patients with hyperphosphatemia.
Topics: Humans; Hyperphosphatemia; Phosphates; Phosphorus; Renal Dialysis; Sodium-Hydrogen Exchanger 3 | 2023 |
2 other study(ies) available for phosphorus and tenapanor
| Article | Year |
|---|---|
Gastrointestinal Inhibition of Sodium-Hydrogen Exchanger 3 Reduces Phosphorus Absorption and Protects against Vascular Calcification in CKD.
Topics: Animals; Calcinosis; Disease Models, Animal; Gastrointestinal Tract; Isoquinolines; Male; Phosphorus; Random Allocation; Rats, Sprague-Dawley; Renal Insufficiency, Chronic; Sodium; Sodium-Hydrogen Exchanger 3; Sodium-Hydrogen Exchangers; Sulfonamides | 2015 |
Combination treatment with tenapanor and sevelamer synergistically reduces urinary phosphorus excretion in rats.
Topics: Animals; Chelating Agents; Drug Synergism; Humans; Intestinal Absorption; Intestinal Mucosa; Isoquinolines; Kidney; Male; Phosphorus; Rats, Sprague-Dawley; Renal Elimination; Sevelamer; Sodium-Hydrogen Exchanger 3; Sulfonamides; Time Factors | 2021 |